{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-21-019494","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2021-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.232669+00:00","generated_at":"2026-06-29T13:19:13.804210+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Co-Diagnostics reports Q2 revenue of $27.4M, EPS $0.33; guides Q3 revenue $23-25M","bullets":["Revenue $27.4M (+13.8% YoY); net income $9.8M ($0.33 diluted EPS) vs $15.0M ($0.51) in Q2 2020.","Gross profit margin 90.8% ($24.9M); operating income $11.8M (-19.8% YoY) due to higher R&D and sales commissions.","Cash and marketable securities $72.4M as of June 30; operating cash flow YTD $24.7M.","Q3 guidance: revenue $23-25M, diluted EPS $0.19-$0.22, effective tax rate ~19%, shares ~30M.","Over 20M tests sold to-date; CE-mark for Logix Smart Direct Saliva test; new international CoPrimer patent."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-21-019494","json":"https://secwatch.observer/filing/0001493152-21-019494.json","markdown":"https://secwatch.observer/filing/0001493152-21-019494.md","text":"https://secwatch.observer/filing/0001493152-21-019494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315221019494/0001493152-21-019494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315221019494/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T13:19:13.804210+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}